A role for AMPA receptors in mood disorders

A Alt, ES Nisenbaum, D Bleakman, JM Witkin - Biochemical pharmacology, 2006 - Elsevier
Major antidepressant agents increase synaptic levels of monoamines. Although the
monoamine hypothesis of depression remains a cornerstone of our understanding of the …

The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence

JM Witkin, MA Statnick, LM Rorick-Kehn… - Pharmacology & …, 2014 - Elsevier
Nociceptin/Orphanin FQ (N/OFQ) is a 17 amino acid peptide that was deorphanized in 1995.
The generation of specific agonists, antagonists and receptor deficient mice and rats has …

Mood disorders: regulation by metabotropic glutamate receptors

A Pilc, S Chaki, G Nowak, JM Witkin - Biochemical pharmacology, 2008 - Elsevier
Medicinal therapies for mood disorders neither fully serve the efficacy needs of patients nor
are they free of side-effect issues. Although monoamine-based therapies are the primary …

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

…, X Li, C Salhoff, FP Bymaster, JM Witkin… - British journal of …, 2003 - Wiley Online Library
In order to explore potential therapeutic implications of cannabinoid antagonists, the effects
of the prototypical cannabinoid antagonist SR141716A on monoamine efflux from the medial …

Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia

…, S Bose, SN Mitchell, JM Witkin… - Proceedings of the …, 2008 - National Acad Sciences
Current antipsychotics provide symptomatic relief for patients suffering from schizophrenia
and related psychoses; however, their effectiveness is variable and many patients discontinue …

Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac)

…, ET Tzavara, JM Witkin… - Proceedings of the …, 2002 - National Acad Sciences
Fluoxetine (Prozac) is the most widely prescribed medication for the treatment of depression.
Nevertheless, little is known about the molecular basis of its clinical efficacy, apart from the …

GABAkines–Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors

…, X Jin, X Ping, LK Golani, JM Cook, JM Witkin - Pharmacology & …, 2022 - Elsevier
Positive allosteric modulators of γ-aminobutyric acid-A (GABA A ) receptors or GABAkines
have been widely used medicines for over 70 years for anxiety, epilepsy, sleep, and other …

Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice

X Li, AB Need, M Baez, JM Witkin - Journal of Pharmacology and …, 2006 - ASPET
Antidepressant-like effects of metabotropic glutamate (mGlu)5 receptor antagonists have
been reported previously. We now provide definitive identification of mGlu5 receptors as a …

A role for cannabinoid CB1 receptors in mood and anxiety disorders

JM Witkin, ET Tzavara, GG Nomikos - Behavioural pharmacology, 2005 - journals.lww.com
Mood and anxiety disorders, the most prevalent of the psychiatric disorders, cause
immeasurable suffering worldwide. Despite impressive advances in pharmacological therapies, …

Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system

JM Witkin, DL Nelson - Pharmacology & therapeutics, 2004 - Elsevier
Evidence exists to implicate the monoamine histamine in the control of arousal and cognitive
functions. Antagonists of H 3 receptors are postsynaptic and presynaptic modulators of …